Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tiziana Life Sciences Ltd (TLSA)

Tiziana Life Sciences Ltd (TLSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 206,821
  • Shares Outstanding, K 116,848
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,860 K
  • EBIT $ 0 M
  • EBITDA $ -16 M
  • 60-Month Beta -0.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 22.74

Options Overview Details

View History
  • Implied Volatility 165.24% (-37.36%)
  • Historical Volatility 56.53%
  • IV Percentile 6%
  • IV Rank 7.56%
  • IV High 1,320.09% on 09/10/25
  • IV Low 70.84% on 12/16/24
  • Expected Move (DTE 14) 0.7650 (43.22%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 88
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 3,227
  • Open Int (30-Day) 3,650
  • Expected Range 1.0050 to 2.5350

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5300 +15.69%
on 11/21/25
1.9000 -6.84%
on 12/02/25
-0.0300 (-1.67%)
since 11/04/25
3-Month
1.5100 +17.22%
on 09/05/25
2.3500 -24.68%
on 09/25/25
+0.1900 (+12.03%)
since 09/04/25
52-Week
0.6295 +181.18%
on 12/31/24
2.6000 -31.92%
on 08/01/25
+0.7500 (+73.53%)
since 12/04/24

Most Recent Stories

More News
Aquestive Therapeutics Announces Leadership Expansion to Support Growth

Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company’s ongoing development initiatives  ...

TLSA : 1.7700 (+4.73%)
AQST : 6.44 (+4.72%)
Tiziana Life Sciences Reports Interim Results and Expands U.S. Presence

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Tiziana Life...

TLSA : 1.7700 (+4.73%)
Uber Stock Ready to Ride Higher on Waymo Partnership

Uber stock may have just found a new way to come back into its growth phase, by seeking a new partnership with Alphabet's Waymo platform.

GOOGL : 317.62 (-0.63%)
TLSA : 1.7700 (+4.73%)
TSLA : 454.53 (+1.74%)
UBER : 90.99 (+0.34%)
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

TLSA : 1.7700 (+4.73%)
AIM : 1.4700 (+5.00%)
PEPG : 5.31 (+1.14%)
AEON : 0.7485 (-8.16%)
MBRX : 7.71 (+1.58%)
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences expands Phase 2 trial for intranasal foralumab in non-active secondary progressive multiple sclerosis across prominent Northeast institutions.Quiver AI SummaryTiziana Life Sciences,...

TLSA : 1.7700 (+4.73%)
Tiziana Life Sciences Receives ALS Association Grant to Advance Clinical Trial of Intranasal Foralumab for ALS Treatment

Tiziana Life Sciences receives funding from the ALS Association for a clinical trial of intranasal foralumab in ALS patients.Quiver AI SummaryTiziana Life Sciences, a biotechnology company focused on immunomodulation...

TLSA : 1.7700 (+4.73%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

TGTX : 31.38 (-0.73%)
TLSA : 1.7700 (+4.73%)
LLY : 1,014.49 (-1.85%)
RHHBY : 48.2000 (-1.47%)
BIIB : 181.98 (+0.68%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

TGTX : 31.38 (-0.73%)
TLSA : 1.7700 (+4.73%)
LLY : 1,014.49 (-1.85%)
RHHBY : 48.2000 (-1.47%)
BIIB : 181.98 (+0.68%)
Gevo's Cash Flow, Small Cap Buying Back Shares

GEVO shareholders may have been sold an empty promise of a sizable share buyback program, or so would bears say. Revenue breakthroughs may deliver the promise

TLSA : 1.7700 (+4.73%)
TSLA : 454.53 (+1.74%)
GEVO : 2.37 (+1.72%)
NIO Could Bring A Pleasant Beat This Coming Quarter

Tesla's price cuts have initiated a full on war across the EV industry, however NIO has refused to follow along. This may present even more upside for the stock

TLSA : 1.7700 (+4.73%)
LCID : 14.15 (+4.35%)
TSLA : 454.53 (+1.74%)
BYDDF : 12.5500 (-0.48%)
NIO : 5.01 (+4.59%)
TCEHY : 78.1200 (-0.50%)
RIVN : 18.06 (+3.02%)

Business Summary

Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 2.0200
2nd Resistance Point 1.9100
1st Resistance Point 1.8400
Last Price 1.7700
1st Support Level 1.6600
2nd Support Level 1.5500
3rd Support Level 1.4800

See More

52-Week High 2.6000
Fibonacci 61.8% 1.8473
Last Price 1.7700
Fibonacci 50% 1.6147
Fibonacci 38.2% 1.3822
52-Week Low 0.6295

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar